Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy
dc.contributor.author | Edlmann, E | |
dc.contributor.author | Giorgi-Coll, S | |
dc.contributor.author | Whitfield, PC | |
dc.contributor.author | Carpenter, KLH | |
dc.contributor.author | Hutchinson, PJ | |
dc.date.accessioned | 2019-11-25T21:44:41Z | |
dc.date.available | 2019-11-25T21:44:41Z | |
dc.date.issued | 2017-12 | |
dc.identifier.issn | 1742-2094 | |
dc.identifier.issn | 1742-2094 | |
dc.identifier.other | 108 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/15180 | |
dc.description.abstract |
Chronic subdural haematoma (CSDH) is an encapsulated collection of blood and fluid on the surface of the brain. Historically considered a result of head trauma, recent evidence suggests there are more complex processes involved. Trauma may be absent or very minor and does not explain the progressive, chronic course of the condition. This review focuses on several key processes involved in CSDH development: angiogenesis, fibrinolysis and inflammation. The characteristic membrane surrounding the CSDH has been identified as a source of fluid exudation and haemorrhage. Angiogenic stimuli lead to the creation of fragile blood vessels within membrane walls, whilst fibrinolytic processes prevent clot formation resulting in continued haemorrhage. An abundance of inflammatory cells and markers have been identified within the membranes and subdural fluid and are likely to contribute to propagating an inflammatory response which stimulates ongoing membrane growth and fluid accumulation. Currently, the mainstay of treatment for CSDH is surgical drainage, which has associated risks of recurrence requiring repeat surgery. Understanding of the underlying pathophysiological processes has been applied to developing potential drug treatments. Ongoing research is needed to identify if these therapies are successful in controlling the inflammatory and angiogenic disease processes leading to control and resolution of CSDH. | |
dc.format.extent | 108- | |
dc.format.medium | Electronic | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.subject | Angiogenesis | |
dc.subject | Chronic subdural haematoma | |
dc.subject | Inflammation | |
dc.subject | Head injury | |
dc.subject | Drug therapy | |
dc.title | Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapy | |
dc.type | journal-article | |
dc.type | Review | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/28558815 | |
plymouth.issue | 1 | |
plymouth.volume | 14 | |
plymouth.publication-status | Published | |
plymouth.journal | Journal of Neuroinflammation | |
dc.identifier.doi | 10.1186/s12974-017-0881-y | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/FoH - Applied Parkinson's Research | |
plymouth.organisational-group | /Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR) | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
plymouth.organisational-group | /Plymouth/Users by role/Researchers in ResearchFish submission | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2017-05-15 | |
dc.identifier.eissn | 1742-2094 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1186/s12974-017-0881-y | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-05-30 | |
rioxxterms.type | Journal Article/Review |